Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 12/20 | 0.81 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.81 |
| ▸ | RXRA | P19793 | 9/20 | 0.55 |
| ▸ | PPARD | Q03181 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 2/20 | 0.39 |
| ▸ | RXRG | P48443 | 2/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1678331 | 0.90 | NR1H2 (1.00) | NR1H2NR1H3RXRAPPARDPPARG | |
| SCHEMBL1678617 | 0.88 | NR1H2 (0.65) | NR1H2NR1H3RXRACYP4A11NR1H4 | |
| SCHEMBL1679010 | 0.87 | NR1H2 (0.67) | NR1H2NR1H3RXRAPPARDPPARG | |
| SCHEMBL1679169 | 0.85 | NR1H2 (0.66) | NR1H2NR1H3RXRAPTGER4SMN1; SMN2 | |
| SCHEMBL1679145 | 0.85 | NR1H2 (0.81) | NR1H2NR1H3RXRAPPARDPPARG | |
| SCHEMBL1679383 | 0.83 | NR1H2 (0.80) | NR1H2NR1H3RXRAPPARDPPARG | |
| SCHEMBL1678799 | 0.83 | NR1H2 (0.80) | NR1H2NR1H3RXRAPPARDPPARG | |
| SCHEMBL1679255 | 0.83 | NR1H2 (0.80) | NR1H2NR1H3RXRAPPARDPPARG | |
| SCHEMBL1678454 | 0.83 | NR1H2 (0.82) | NR1H2NR1H3RXRAPPARDPPARG | |
| SCHEMBL1678576 | 0.83 | NR1H2 (0.82) | NR1H2NR1H3RXRAPPARDPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923573-B2 | Benzene compound having 2 or more substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-12 | — | — | US | disclosed |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-03 | — | — | US | disclosed |
| EP-1806332-A1 | BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS | Daiichi Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | NR1H2, NR1H3, NCOR2 | NR1H2 1/4885NR1H3 2/4885RXRA 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.